HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Clinical Trial: Drug that Stops Myeloma Progression with Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Posted: Jun 26, 2017
Clinical Trial: Drug that Stops Myeloma Progression with Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma image
TGF-β, a multifunctional cytokine, is produced in multiple myeloma cells and cells in the bone marrow environment and stimulates myeloma progression. A new drug called  TEW-797 targets this cytokine and kills myeloma cells alone and with other myeloma drugs.
“Our data demonstrate that TEW-7197 effectively modulates the MM TME and is associated with a potent anti-myeloma effect in an immunocompetent murine model of MM,” lead author Byung-gyu Kim, DVM, of Case Western Reserve University in Cleveland, Ohio, said during his presentation of the results of a study using this drug with ixazomib.
  TEW-7197 is now in a clinical trial with pomalidomide for relapse/refractory myeloma patients. The trial is open at two sites in Ohio. To learn more about this clinical trial, click here: Pomalidomide and TEW-7197 Clinical Trial
The author Allyse Shumway

about the author
Allyse Shumway

MyelomaCrowd Editorial Contributor. Daughter to a parent with cancer.

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube